Pathological response with bevacizumab colorectal liver metastases: Cological and pathological review

Cancer and Chemotherapy Reviews

Volumn 7, Issue 4, 2012, Pages 173-178

  Garcia, Ruth Vera ^a   Dorronsoro, Marisa Gómez ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Bevacizumab; Colorectal cancer; Histological study; Liver metastases; Pathological response; Prognostic impact; RECIST

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IMATINIB; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER THERAPY; COLORECTAL CANCER; HUMAN; LIVER HISTOLOGY; LIVER METASTASIS; LIVER RESECTION; RADIODIAGNOSIS; REVIEW; TUMOR CELL; TUMOR REGRESSION;

EID: 84876212733     PISSN: 1885740X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist. 2007;12:825-39.
2. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for respectability of colorectal liver metastases. Oncologist. 2008;13:51-64.
3. Nordlinger B, van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009; 20:985-92.
4. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006;33 (Suppl. 10):S1-7.
5. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-16.
6. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unrespectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829-35.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44.
9. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-19.
10. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-5.
11. Okines A, Puerto OD, Cunningham D, et al. Surgery with curative- intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-Ill N016966 trial. Br J Cancer. 2009;101:1033-8.
12. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLF- OXIRI (irinotecan, oxaliplatin, fluorouracil and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845-52.
13. Zorzi D, Chun YS, Madoff DC, et al. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 2008;15:2765-72.
14. Aussilhou B, Dokmak S, Faivre S, et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol. 2009;16:1553-59.
15. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338-44.
16. Rubbia-Brandt L, Giostra E, Brezault C. et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007; 18:299- 304, "First description of pathologic response quantification in CRLM in patients treated with chemotherapy before resection.
17. Klinger M, Tamandl D, Eipeldauer S, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 2010; 17:2059-65. "In the setting of neoadjuvant treatment of liver metastases, addition of bevacizumab to chemotherapy has shown an improvement of the pathological response, and has been associated to better survival for patients with resected CRLM.
18. Blazer DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344-51.
19. Li Chang HH, Leeper R, Chan G, et al. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma metastases treated with perioperative chemotherapy. Am J Surg Pathol. 2012; 36:570-6.
20. Poulsides GA, Bao F, Servais EL, et al. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol. 2012;19:2797-804.
21. Maru D, Kopetz S, Boonsirikamchai P, et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010;34:1287-94.
22. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835-44.
23. Malavasi N, Ponti G, Depenni R, et al. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. J Hematol Oncol. 2009;2:35-9.
24. Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012;21(4):309-15.
25. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635-41.
26. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761-7.
27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
28. Grothey A, Hedrick EE, Mass RD, et al. Response-Independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008; 26:183-9.
29. Boonsirikamchai P, Asran MA, Maru DM, et al. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR Am J Roentgenol. 2011;197:W1060-6.